izpis_h1_title_alt

Distinctive immune signatures driven by structural alterations in desmuramylpeptide NOD2 agonists
ID Janež, Špela (Author), ID Guzelj, Samo (Author), ID Kocbek, Petra (Author), ID de Vlieger, Eveline A. (Author), ID Slütter, Bram (Author), ID Jakopin, Žiga (Author)

.pdfPDF - Presentation file, Download (4,81 MB)
MD5: 9755E7D8071353759D9507AA4F6447D7
URLURL - Source URL, Visit https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c01577 This link opens in a new window

Abstract
Herein we report on the design, synthesis and biological evaluation of a series of nucleotide-binding oligomerization-domain-containing protein 2 (NOD2) desmuramylpeptide agonists. The structural prerequisites that shape both physicochemical and immunomodulatory profiles of desmuramylpeptide NOD2 agonists have been delineated. Within this context, we identified 3, a butyrylated desmuramylpeptide, as a potent in vitro NOD2 agonist (EC$_{50}$ = 4.6 nM), exhibiting an almost 17-fold enhancement in potency compared to its unsubstituted counterpart 1 (EC$_{50}$ = 77.0 nM). The novel set of desmuramylpeptides demonstrate unique in vitro immunomodulatory activities. They elicited cytokine production in peripheral blood mononuclear cells (PBMCs), both alone and in conjunction with lipopolysaccharide (LPS). The spermine-decorated 32 also stimulated the LPS-induced cytotoxic activity (2.95-fold) of PBMCs against K562 cancer cells. Notably, the cholesterol-conjugate 26 displayed anti-inflammatory actions, highlighted by its capacity to convert the inflammatory monocyte subset into an anti-inflammatory phenotype. Finally, the eicosapentaenoylated derivative 23 augmented antigen presentation by mouse bone marrow-derived dendritic cells (BMDCs), thus highlighting its potential as a vaccine adjuvant.

Language:English
Keywords:agonists, cells, peptides, proteins, reaction products, toxicity
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2024
Number of pages:Str. 17585–17607
Numbering:Vol. 67, iss. 19
PID:20.500.12556/RUL-163778 This link opens in a new window
UDC:615.9+615.375
ISSN on article:1520-4804
DOI:10.1021/acs.jmedchem.4c01577 This link opens in a new window
COBISS.SI-ID:209432835 This link opens in a new window
Publication date in RUL:10.10.2024
Views:106
Downloads:48
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Journal of medicinal chemistry
Shortened title:J. med. chem.
Publisher:American Chemical Society
ISSN:1520-4804
COBISS.SI-ID:512806681 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:agonisti, celice, peptidi in proteini, reakcijski produkti, toksičnost, imunomodulatorji

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0420
Name:Napredna imunološka zdravila in celični pristopi v farmaciji

Funder:ARRS - Slovenian Research Agency
Project number:J3-2517
Name:Razvoj himernih multiplih agonistov receptorjev prirojene imunosti kot učinkovitih adjuvansov za cepiva

Funder:ARRS - Slovenian Research Agency
Project number:J3-4496
Name:Adjuvansi naslednje generacije za mukozna cepiva

Funder:ARRS - Slovenian Research Agency
Funding programme:Young researchers

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back